From CLEOPATRA to DESTINY-Breast09: A Decade of Change in Metastatic HER2+ Disease

For over a decade, the CLEOPATRA trial stood unchallenged. Now, the paradigm is shifting.

This clip explores the transition from traditional taxane-based therapy to the emerging ADC landscape. Hear our experts examine why the field is moving away from the old standard to prioritize more durable responses, improved quality of life, and a more sophisticated approach to both systemic and CNS disease.